PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Background: ROR1 is an oncofetal protein expressed in various blood and solid cancers. Zilovertamab vedotin (ZV) is an antibody-drug conjugate comprising a monoclonal antibody against ROR1, a ...

Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...

A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...

Eligible patients were women with stage IV breast cancer who had moderate to severe fatigue interference. Patients completed a baseline assessment that included self-report measures of fatigue ...

Thromboembolic adverse events are preventable. In a large randomized controlled trial (RCT) of primary thromboprophylaxis with rivaroxaban 10 mg once daily (v placebo) in ambulatory patients with ...

Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD (L)1 ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Health care delays (postponement of medical care) are a significant barrier to optimal care for cancer survivors, particularly among adolescent and young adults (AYAs). 1 - 3 Despite overall ...

A total of 167 patients underwent random assignment, 82 patients to SCS plus HIPEC (experimental arm) and 85 to SCS alone (control arm). The median follow-up was 83 months (IQR, 64-102). The median ...

Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results in patients (pts) with locally advanced/metastatic ...